AllSci News
Attovia Therapeutics launches IPO backed by USD 255.8m in nanobody platform funding
Attovia Therapeutics Inc (Nasdaq: ATTO), a clinical-stage immunology company whose nanobody-based biologics platform has attracted USD 255.8 million in...
Boehringer Ingelheim advances first-in-class triple receptor agonist BI 3034701 into Phase II obesity trial
Boehringer Ingelheim has announced the start of a Phase II trial for BI 3034701, a triple GLP-1/GIP/NPY2 receptor agonist, in adults with obesity or...
Sinopia Bio's PKA-II modulator demonstrates dyskinesia reduction in preclinical Parkinson's models
<a...
AdvanCell secures USD 315m to advance Lead-212 alpha therapy into Phase III study
AdvanCell, a clinical-stage radiopharmaceutical company with dual headquarters in Andover, Massachusetts and Brisbane, Australia, has closed an...
Summit divests ridinilazole as oncology strategy takes center stage
Summit Therapeutics (Nasdaq: SMMT) has agreed to sell ridinilazole, a narrow-spectrum antibiotic that completed Phase III development for Clostridioides...
Ligand doubles royalty portfolio to 200 assets with USD 739 million XOMA Royalty acquisition
Ligand Pharmaceuticals (Nasdaq: LGND) has completed its acquisition of XOMA Royalty Corporation for USD 739 million in cash, more than doubling its royalty...
Lōkahi goes public through Glucotrack merger, controls combined company with 90% stake
Lōkahi Therapeutics has completed its strategic business combination with Rutherford, New Jersey-based Glucotrack, Inc. (Nasdaq: GCTK), establishing a...
Insilico extends Pharma.AI strategy downstream in USD 2.5 billion Bora alliance
Insilico Medicine (HKEX: 3696) and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY) announced a multi-target strategic alliance pairing Insilico’s AI drug…
US FDA converts Lilly’s tissue-agnostic Retevmo approval to traditional approval
The US FDA has granted traditional approval to Retevmo (selpercatinib) for adult and pediatric patients aged two and older with locally advanced…
Biogen's diranersen misses Phase II primary endpoint but shows encouraging tau-targeting signal in Alzheimer's
Biogen's diranersen (BIIB080) produced reductions in tau biomarkers and a signal of slowed cognitive decline in early Alzheimer's disease, but the Phase II...
Kelun-Biotech's sac-TMT meets Phase III endpoint in first-line PD-L1-negative NSCLC
Sichuan Kelun-Biotech Biopharmaceutical (HKEX: 6990.HK) has reported that its Phase III OptiTROP-Lung06 trial of sacituzumab tirumotecan (sac-TMT, also...
Senti Biosciences spins out gene-circuit pipeline into NewCo to focus on Regulator Dial platform
South San Francisco-based Senti Biosciences Holdings (Nasdaq: SNTI) is divesting its gene-circuit-enabled pipeline — including its most advanced clinical...
SHY Therapeutics begins first-in-human trial of novel 19S proteasome inhibitor SHY-ONC6
SHY Therapeutics has begun a Phase I FIH clinical trial of SHY-ONC6, a novel proteasome inhibitor targeting the 19S regulatory particle of the 26S...
Septa acquires CeeNU from BMS to end Canada's critical chemotherapy shortage
Mississauga, Ontario-based Septa Pharmaceuticals has acquired CeeNU (lomustine) from Bristol Myers Squibb (NYSE: BMY) Canada, effective June 29, 2026,...
FDA approves Celcuity’s Revtorpyk as first dual PI3K/mTOR inhibitor for PIK3CA wild-type breast cancer
Minneapolis-based Celcuity Inc. (Nasdaq: CELC) has received US FDA approval for Revtorpyk (gedatolisib), making it the first and only therapy to inhibit…
The AllSci Brief
Systematic R&D and deal news. Daily.